Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel

A Randomized, Observer-Blinded, Within Patient Bilateral Comparison to Study the Safety and Efficacy of Daily Application for 4 Weeks of DBI-001 Gel Versus Aqueous Gel in Subjects With Atopic Dermatitis

The purpose for this study is to assess the Safety and Efficacy of Daily Application for 4 weeks of DBI-001 Gel Versus Aqueous Gel in Subjects with Atopic Dermatitis

Study Overview

• Status: Terminated
• Conditions: Atopic Dermatitis
• Intervention / Treatment: Biological: DBI-001; Biological: Aqueous gel

Detailed Description

This is a randomized, observer blinded, Aqueous Gel-controlled, within-patient, bilateral comparison trial examining the effect of daily application for 4 weeks of DBI-001 Gel vs. Aqueous Gel on the clinical Atopic Dermatitis Severity Index (ADSI) scores and the abundance of Staphylococcus aureus of comparable bilateral target sites of Atopic Dermatitis (AD), as well as signs and symptoms of local tolerability on treated sites in subjects.

Subjects meeting the inclusion/exclusion criteria and having moderate to severe AD lesions at screening and baseline/Day 1 will be enrolled into the study.

In an observer-blinded fashion, each subject will have two sites randomly assigned to have either DBI-001 Gel or Aqueous Gel applied to the designated treatment targeted sites.

After Screening, Study visits will occur at Day 1 Baseline then Days 7 (±2), 14 (±2), 21 (±2), 28 (±2), 35 (±4), and 42 (±4)

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Scottsdale, Arizona, United States, 85255
      • Investigate MD, LLC
  • Texas
    • Austin, Texas, United States, 78759
      • Dermresearch, Inc.
  • Washington
    • Mill Creek, Washington, United States, 98012
      • North Sound Dermatology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years to 65 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• 1. Ability to understand, agree to, and sign the study Informed Consent. If the patient is unable to provide consent for him/herself, the patient's legally authorized representative may provide written consent.
• 2. A signed Health Information Portability and Accountability Act (HIPAA) authorization form which permits the use and disclosure of subject's individually identifiable health information.
• 3. Male or Female Subjects of any race 12 - 65 years of age.
• 4. Physician diagnosed clinically stable AD according to the criteria of Hanifin and Rajka with symmetrical bilateral target lesions (Hanifin and Rajka 1980). Lesion on each arm or leg must have an Atopic Dermatitis Severity Index (ADSI) ≥6. The 2 sites need to be comparable anatomically symmetrical sites. It will be in the opinion of the Investigator based on subject's medical history whether the lesions are clinically stable.
• 5. Female patients of child-bearing potential must use at least one method of birth control that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomized partner for the duration of study participation.
• 6. Technical ability and willingness to apply test articles during telemedicine visits with the study staff and unsupervised on weekends.
• 7. Willingness to discontinue use of systemic AD treatments and topical treatments to the target areas for the duration of the study unless specifically permitted by the Investigator.

• 8. Willingness to comply with test site restriction for 12 hours prior to all office visits including the Baseline visit and for 12 hours after each treatment application. These treatment site restrictions include:

  1. No washing of test sites with any cleansers or soaps at any time from the Baseline visit to completion of the Day 42 Follow up Visit. Water passing over the areas during showering is acceptable.
  2. No rubbing the test sites with a washcloth, towel, luffas. Pat dry after showering is acceptable.
  3. No recreational activities in chlorinated or chemically treated water such as swimming pools, hot tubs, and spas.
  4. No tight or form fitting clothing covering the treatment areas.
  5. No sunbathing or use of suntan parlors or tanning beds.
  6. If participating in physical activities resulting in heavy perspiration only pat dry test site areas with towel if needed.
  7. Any activity that in the opinion of the investigator might alter the quality of the samples collected or risk removal of the test article.

• 9. Willingness to undergo the following washout periods:

  1. Washout of 2 weeks prior to the Baseline visit for topical treatments used on the two treatment target sites, including but not limited to: antibacterial products, anti-inflammatories (e.g., corticosteroids, tacrolimus, Pimecrolimus). Other than the two sites on the arms or legs, topical medications may be used before/during the duration of the study. Subjects will be provided 1% hydrocortisone for treating non-target areas during the trial.
  2. Washout of 4 weeks prior to the Baseline visit for systemic treatments for AD, including but not limited to corticosteroids (oral or intramuscular injections), systemic immunomodulators or immunosuppressive (e.g., methotrexate, cyclosporine, hydroxychloroquine), antibiotics (oral or injected, if required to treat a medical condition short duration of oral antibiotics (≤10 days) are permitted after randomization)
  3. Washout of 2 weeks prior to the Baseline visit for bleach baths.
  4. Washout of 2 weeks prior to the Baseline visit for phototherapy.
• 10. No history of allergy to at least two of the following classes of antibiotics: Cephalosporin, Quinolone, Tetracycline, Aminoglycosides Macrolide, Carbapenems and Lipopeptides.
• 11. Willingness to allow digital photos of arms or legs to be taken and stored.

Exclusion Criteria:

• 1. Women who are pregnant, planning a pregnancy, breastfeeding or have a positive pregnancy test at screening.
• 2. Any dermatological conditions that could interfere with clinical evaluations or any disease state or physical condition which might expose the patient to an unacceptable risk by study participation.
• 3. Any underlying disease(s) or other dermatological conditions that require the use of exclusionary topical or systemic therapy.
• 4. Spontaneously improving or rapidly deteriorating dermatitis anywhere on the body.
• 5. Netherton's syndrome or other genetic dermatoses that result in defective epidermal barrier function.
• 6. Treatment of any type of cancer within the last 6 months other than cutaneous basal cell carcinoma.
• 7. History of any significant internal disease (which contraindicates use of live microbiome e.g. leukemia, liver failure, cardiovascular disease).
• 8. Subjects who are known to be allergic to any of the test product(s) or any components in the test product(s) or history of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure.
• 9. AIDS or AIDS related complex by medical history.
• 10. Known or suspected immune suppressive medications or diseases or any condition that in the opinion of the investigator would increase the subject's susceptibility to opportunistic infections. 11. Treatment with systemic immune modulating or anti-inflammatory biologics agents within 16 weeks of Baseline Visit.
• 12. Poorly controlled diabetes mellitus Type I or II by medical history.
• 13. Peripheral vascular disease based on medical history.
• 14. Any subject not able to meet the study attendance and telemedicine visit requirements.
• 15. Participants with a history of psychiatric disease or history of alcohol or drug abuse that would interfere with the ability to comply with the study protocol.
• 16. Subjects who have participated in any other trial of an investigational drug or device within 30 days prior to enrollment or participation in a research study concurrent with this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: DBI-001 Gel; DBI-001 Gel: Topical application of DBI-001 gel on skin affected with atopic dermatitis. (This study is a within-subject bilateral controlled study)	Biological: DBI-001; Topical application of DBI-001 gel on skin affected with atopic dermatitis.
Placebo Comparator: Aqueous Gel; Aqueous Gel: Topical application of aqueous gel on skin affected with atopic dermatitis. (This study is a within-subject bilateral controlled study)	Biological: Aqueous gel; Topical application of aqueous gel on skin affected with atopic dermatitis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Individual Signs and Symptoms of Atopic Dermatitis	Change from baseline in individual signs and symptoms of Atopic Dermatitis (components of the ADSI score) at days 7, 14, 21, 28, 35, and 42 of sites treated with DBI-001 Gel or Aqueous Gel Atopic Dermatitis Severity Index: The ADSI score represents the sum of the individual severity scores of none, mild, moderate, or severe for the following component signs and symptoms: erythema, pruritus, exudation, excoriation, and lichenification. To calculate the ADSI score, the component scores are added together. Scale for the individual components: 0=none; mild; moderate; severe	42 days of participation

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of subjects with treatment-related adverse events	Safety	42 days of participation
Molecular diagnostic qPCR comparison of DBI-001 drug product with aqueous gel	Antimicrobial efficacy	42 days of participation
Change in colony forming units	Antimicrobial efficacy	42 days of participation
Proportion of subjects with a greater decrease in Atopic Dermatitis Severity Index	Observe proportion of subjects with a greater decrease in Atopic Dermatitis Severity Index for sites treated with DBI-001 Gel or Aqueous Gel.	42 days of participation
Change in colony forming units after using DBI-001 drug product or aqueous gel	Antimicrobial efficacy	42 days of participation
Number of subjects with treatment-related changes in the immune system response after using DBI-001 drug product or aqueous gel as assessed by changes in the stratum corneum.	Clinical Efficacy	42 days of participation

Collaborators and Investigators

• Sponsor: DermBiont, Inc.
• Collaborators: Derm Research, PLLC; Northsoundderm; ClearDermatologyandAestheticsCenter

Study record dates

Study Major Dates

• Study Start (Actual): October 6, 2021
• Primary Completion (Actual): September 9, 2022
• Study Completion (Actual): September 9, 2022

Study Registration Dates

• First Submitted: November 1, 2021
• First Submitted That Met QC Criteria: February 14, 2022
• First Posted (Actual): February 24, 2022

Study Record Updates

• Last Update Posted (Estimated): November 8, 2023
• Last Update Submitted That Met QC Criteria: October 20, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Immune System Diseases; Hypersensitivity, Immediate; Genetic Diseases, Inborn; Skin Diseases, Genetic; Hypersensitivity; Skin Diseases, Eczematous; Dermatitis; Eczema; Dermatitis, Atopic
• Other Study ID Numbers: DBI-207

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No